Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
425.60 CHF | +0.83% | -0.16% | -6.07% |
Sep. 28 | AlphaValue/Baader Europe Lowers Price Target on Lonza Group, Maintains Buy Recommendation | MT |
Sep. 21 | Swiss Pharmaceutical Manufacturing Group Lonza Reiterates FY23 Outlook | MT |
Sales 2023 * | 6,413 M 7,006 M | Sales 2024 * | 7,114 M 7,771 M | Capitalization | 31 614 M 34 535 M |
---|---|---|---|---|---|
Net income 2023 * | 884 M 966 M | Net income 2024 * | 1,107 M 1,209 M | EV / Sales 2023 * | 5,16x |
Net Debt 2023 * | 1,477 M 1,613 M | Net Debt 2024 * | 2,320 M 2,535 M | EV / Sales 2024 * | 4,77x |
P/E ratio 2023 * | 34,7x | P/E ratio 2024 * | 27,1x | Employees | - |
Yield 2023 * | 0,85% | Yield 2024 * | 0,91% | Free-Float | 99.70% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
1 day | +0.83% | ||
1 week | -0.16% | ||
Current month | -12.95% | ||
1 month | -11.31% | ||
3 months | -18.62% | ||
6 months | -20.60% | ||
Current year | -6.07% |
1 week
414.90
436.80

1 month
414.90
502.80

Current year
414.90
599.40

1 year
414.90
599.40

3 years
414.90
785.40

5 years
245.10
785.40

10 years
71.75
785.40

Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.77% | 30 M$ | +5.20% | - | |
0.95% | 47 M$ | +8.73% | ||
0.56% | 6 M$ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
23-09-29 | 425.60 | +0.83% | 238,940 |
23-09-28 | 422.10 | -.--% | 219,113 |
23-09-27 | 422.10 | -2.38% | 260,396 |
23-09-26 | 432.40 | +0.07% | 210,820 |
23-09-25 | 432.10 | +1.36% | 218,525 |
Delayed Quote Swiss Exchange, September 29, 2023 at 11:30 am EDT
More quotes
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows:
- bio-pharmaceuticals (49.9%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.;
- capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (22.3%). In addition, the group offers nutritional ingredients;
- small molecule drug substances (14.2%);
- technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%);
- other (2.5%).
Net sales break down geographically as follows: Switzerland (9.7%), Europe (28.3%), the United States (42.3%), Americas (3.8%), Asia (14.2%), Australia and New Zealand (1.3%), Africa (0.3%) and other (0.1%).
Calendar
2023-10-17
- Capital Markets Day
Trading Rating :
Investor Rating :
ESG Refinitiv :
A
Sell
Buy

Mean consensus
BUY
Number of Analysts
18
Last Close Price
425.60CHF
Average target price
627.41CHF
Spread / Average Target
+47.42%
EPS Revisions
1st Jan change | Capi. (M$) | |
---|---|---|
-6.07% | 34 570 M $ | |
+115.74% | 91 M $ | |
+0.99% | 50 M $ | |
+36.03% | 247 M $ | |
-.--% | 1 789 M $ | |
-54.24% | 60 M $ | |
-12.06% | 620 M $ | |
-39.18% | 796 M $ | |
-59.44% | 132 M $ | |
+22.70% | 897 M $ |